Antibodies to ticagrelor and methods of use
The disclosure generally provides antibodies and antigen binding fragments of antibodies that bind ticagrelor and metabolites of ticagrelor. The disclosure also provides compositions comprising the antibodies, nucleic acid molecules encoding the antibodies, methods of treating a patient comprising administering the antibodies, and methods of making and using the antibodies.
1. An antibody or a fragment thereof that specifically binds a cyclopentyltriazolopyrimidine compound of the Formula (Ia):
wherein
R 1 is selected from the group consisting of C 1 -C 6 alkoxy and C 1 -C 6 alkylthio;
R 2 is selected from the group consisting of H, C 1 -C 6 alkyl, substituted C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, and substituted C 3 -C 6 cycloalkyl; and
R 3 is selected from the group consisting of H, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, and C 1 -C 6 alkanol;
wherein the antibody or a fragment thereof comprises the complementarity-determining regions (CDR) of:
SEQ ID NO:73 (VH CDR1), SEQ ID NO:74 (VH CDR2), SEQ ID NO:75 (VH CDR3), SEQ ID NO:78 (VL CDR1), SEQ ID NO:79 (VL CDR2), and SEQ ID NO:80 (VL CDR3).
2. The antibody or fragment thereof of claim 1 , wherein the antibody or fragment thereof is selected from a monoclonal antibody, a humanized antibody, a human antibody, a single chain Fv (scFv), a Fab, a F(ab′) 2 , a single chain diabody, and an antibody mimetic.
3. The antibody or fragment thereof of claim 1 , wherein the antibody or fragment thereof binds ticagrelor or an active metabolite thereof.
4. The antibody or fragment thereof of claim 3 , wherein the antibody or fragment thereof neutralizes the antiplatelet effect of ticagrelor or an active metabolite thereof.
5. The antibody or fragment thereof of claim 4 , wherein the antibody or fragment thereof neutralizes the antiplatelet effect of ticagrelor or an active metabolite thereof within about 60 minutes after administration to a patient.
6. The antibody or fragment thereof of claim 5 , wherein the antibody or fragment thereof neutralizes the antiplatelet effect of ticagrelor or an active metabolite thereof within about 30 minutes after administration to a patient.
7. The antibody or fragment thereof of claim 3 , wherein the antibody or fragment thereof restores ADP-induced platelet aggregation in the presence of ticagrelor or an active metabolite of ticagrelor.
8. The antibody or fragment thereof of claim 3 , wherein the antibody or fragment thereof inhibits the effect of ticagrelor or an active metabolite thereof on the P2Y12 receptor.
9. The antibody or fragment thereof of claim 3 , wherein the antibody or fragment thereof binds ticagrelor or an active metabolite thereof with an equilibrium KD of about 50 nM or lower.
10. The antibody or fragment thereof of claim 1 , wherein the antibody or fragment thereof has an in vivo half-life of about 4-24 hours.
11. An antibody or fragment thereof comprising the complementarity-determining regions (CDR) of: SEQ ID NO:73 (VH CDR1), SEQ ID NO:74 (VH CDR2), SEQ ID NO:75 (VH CDR3), SEQ ID NO:78 (VL CDR1), SEQ ID NO:79 (VL CDR2), and SEQ ID NO:80 (VL CDR3).
12. The antibody or fragment thereof of claim 11 , wherein the antibody or fragment thereof is selected from a monoclonal antibody, a humanized antibody, a human antibody, a single chain Fv (scFv), a Fab, a F(ab′)2, a single chain diabody, and an antibody mimetic.
13. The antibody or fragment thereof of claim 11 , wherein the antibody or fragment thereof binds ticagrelor or an active metabolite thereof.
14. A Fab comprising the complementarity-determining regions (CDR) of:
SEQ ID NO:73 (VH CDR1), SEQ ID NO:74 (VH CDR2), SEQ ID NO:75 (VH CDR3), SEQ ID NO:78 (VL CDR1), SEQ ID NO:79 (VL CDR2), and SEQ ID NO:80 (VL CDR3).
15. The Fab of claim 14 , wherein the antibody or fragment thereof binds ticagrelor or an active metabolite thereof.